References
- Tufts NEWDIGS. Precision financing solutions for durable/potentially curative therapies. [Internet]. Center for biomedical system design, institute for clinical research and health policy studies. Tufts Med Center. 2019 [Cited 2022 Mar 15]. Available from. https://newdigs.tuftsmedicalcenter.org/precision-financing-solutions-for-durable-potentially-curative-therapies/
- Gottlieb S, Kk P. A fair plan for fairer drug prices | health affairs forefront [Internet]. [Cited 2022 Mar 15]. Available from: https://www.healthaffairs.org/do/10.1377/forefront.20160711.055778/full/.
- Garrison LP, Towse A, Briggs A, et al. Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value in Health. 2013;16:703–719.
- AMCP Partnership Forum. Advancing value-based contracting. J Manag Care Spec Pharm. 2017;23:1096–1102.
- Tufts NEWDIGS. In: Policy actions for enabling precision financing Solutions [Internet]. Center for biomedical system design, institute for clinical research and health policy studies. Tufts Medical Center. 2021 [Cited 2022 Mar 15]. Available fromhttps://newdigs.tuftsmedicalcenter.org/wp-content/uploads/2021/02/P4C-Policy-Actions-201123.pdf
- Garrison LP, Jackson T, Paul D, et al. Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold. J Manag Care Spec Pharm. 2019;25:793–799.
- Wenzl M, Chapman S. Performance-based managed entry agreements for new medicines in OECD countries and EU member states: how they work and possible improvements going forward [Internet]. 2019 [Cited 2022 Mar 15]. Report No.: 115. Available from: https://www.oecd-ilibrary.org/social-issues-migration-health/performance-based-managed-entry-agreements-for-new-medicines-in-oecd-countries-and-eu-member-states_6e5e4c0f-en.
- Neumann PJ, Chambers JD, Simon F, et al. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Aff (Millwood). 2011;30:2329–2337.
- Ward AS, Linthicum MT, Drozd M, et al. Regulatory, legal uncertainties are barriers to value-based agreements for drugs. Health Affairs Blog. 2016;November 4.
- Goodman C, Villarivera C, Gregor K, et al. Regulatory, policy, and operational considerations for outcomes-based risk-sharing agreements in the. U S Market: Opportunities for Reform JMCP. 2019;25:1174–1181.
- White J. Medicaid “best price” approach to drug costs needs an upgrade [Internet]. STAT. 2017 [Cited 2023 Mar 8]. Available from: https://www.statnews.com/2017/11/10/drug-pricing-medicaid-value-based/.
- Sachs R, Bagley N, Lakdawalla DN. Innovative contracting for pharmaceuticals and medicaid’s best-price rule. J Health Polit Policy Law. 2018;43:5–18.
- Verma S. CMS’s proposed rule on value-based purchasing for prescription drugs: new tools for negotiating prices for the next generation of therapies. Health Affairs Blog. Internet]. 2020 [Cited 2023 Mar 8];June 17. Available from.;. https://www.healthaffairs.org/do/10.1377/forefront.20200617.728496/full/
- Garfield R, Dolan R. Costs and savings under federal policy approaches to address medicaid prescription drug spending [Internet]. KFF. 2021 Cited 2023 Mar 8;2021: Available from. https://www.kff.org/medicaid/issue-brief/costs-and-savings-under-federal-policy-approaches-to-address-medicaid-prescription-drug-spending/
- Glossary of common industry terms. [Internet]. Drug Pricing Lab. [Cited 2023 Mar 8] . Available from: https://www.drugpricinglab.org/tools/glossary/.
- Quinn C, Ciarametaro M, Sils B, et al. Medicaid best price reforms to enable innovative payment models for cell and gene therapies. Expert Rev Pharmacoecon Outcomes Res. 2022;0:1–13.
- MIT NEWDIGS FoCUS Project. Toolkit overview: precision financing solutions [Internet]. Paying for Cures. [Cited 2023 Mar 8]. Available from: https://payingforcures.mit.edu/toolkit-overview/precision-financing-solutions/.
- Trusheim MR, Cassidy WM, Bach PB. Alternative state-level financing for hepatitis C treatment—the “Netflix model.” JAMA. 2018;320:1977–1978.
- van Overbeeke E, Michelsen S, Toumi M, et al. Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discov Today. 2021;26:399–415.
- APEC. APEC Action Plan. On Rare Diseases [Internet]. 2018 [Cited 2023 Mar 8]. Available from: https://www.apec.org/docs/default-source/satellite/Rare-Diseases/APEC_ActionPlan.pdf.
- Fingertip FormularyTM Suite [Internet]. Decision Resources Group. [cited 2020 Jan 1]. Available from: https://decisionresourcesgroup.com/solutions/drg-knows-formulary/.